Clinical Trial Update: A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) [Phase 3]

View source ↗

Summary

Phase 3 trial update for PF-05280586 (rituximab-Pfizer) vs MabThera (rituximab-EU) as first-line treatment in CD20-positive, low tumor burden follicular lymphom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• PF-05280586
• Rituximab (MabThera) (Rituximab)

Snippet

Sponsor: Pfizer | Conditions: Follicular Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2018-10-30